Zacks Investment Research upgraded shares of Cardinal Health, Inc. (NYSE:CAH) from a sell rating to a hold rating in a research report report published on Wednesday.

According to Zacks, “Over the last year, Cardinal Health has underperformed the broader industry with respect to price. Increasing generic pricing pressure is a major headwind. Intensifying competition and customer concentration are other bottlenecks. A sluggish macroeconomic scenario and tough product pricing environment are likely to impede growth. Meanwhile, the company is banking on strategic buyouts, joint ventures and supply agreements to drive growth. A solid fiscal 2018 guidance instills our confidence in the stock. Also, Cardinal Health ended first-quarter on a solid note, courtesy of an encouraging performance at the Medical segment. Although, the Pharmaceutical segment witnessed strong growth in the Specialty business and gained a huge number of Pharmaceutical Distribution customers, profits at the segment were hurt by generic pharmaceutical pricing and the loss of a major Pharmaceutical Distribution customer.”

A number of other equities research analysts have also issued reports on CAH. Jefferies Group LLC cut their price objective on shares of Cardinal Health from $77.00 to $67.00 and set a hold rating for the company in a report on Tuesday, November 7th. BidaskClub lowered shares of Cardinal Health from a hold rating to a sell rating in a report on Friday, August 4th. Credit Suisse Group cut their price objective on shares of Cardinal Health from $87.00 to $81.00 and set an outperform rating for the company in a report on Thursday, August 3rd. UBS AG reaffirmed a neutral rating and set a $76.00 price objective (down from $79.00) on shares of Cardinal Health in a report on Wednesday, August 9th. Finally, Cowen and Company reaffirmed a market perform rating and set a $77.00 price objective (down from $82.00) on shares of Cardinal Health in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $74.81.

Shares of Cardinal Health (NYSE:CAH) traded down $2.01 on Wednesday, reaching $58.55. 8,061,600 shares of the company’s stock were exchanged, compared to its average volume of 3,498,619. The company has a debt-to-equity ratio of 1.35, a quick ratio of 0.80 and a current ratio of 1.06. Cardinal Health has a twelve month low of $57.54 and a twelve month high of $84.88. The stock has a market cap of $18,420.06, a price-to-earnings ratio of 11.11, a P/E/G ratio of 1.69 and a beta of 0.88.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings data on Monday, November 6th. The company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. Cardinal Health had a net margin of 0.84% and a return on equity of 25.24%. The business had revenue of $32.64 billion during the quarter, compared to analyst estimates of $33.48 billion. During the same period last year, the firm posted $1.24 EPS. The company’s revenue was up 1.9% on a year-over-year basis. equities research analysts expect that Cardinal Health will post 4.97 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/cardinal-health-inc-cah-stock-rating-upgraded-by-zacks-investment-research/1698435.html.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Tuesday, January 2nd will be issued a $0.4624 dividend. This represents a $1.85 dividend on an annualized basis and a dividend yield of 3.16%. The ex-dividend date is Friday, December 29th. Cardinal Health’s dividend payout ratio (DPR) is presently 53.78%.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bronfman E.L. Rothschild L.P. boosted its stake in Cardinal Health by 31.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 1,583 shares of the company’s stock worth $123,000 after buying an additional 382 shares during the period. Advisory Services Network LLC boosted its stake in Cardinal Health by 18.4% during the second quarter. Advisory Services Network LLC now owns 1,739 shares of the company’s stock worth $136,000 after buying an additional 270 shares during the period. JFS Wealth Advisors LLC boosted its stake in Cardinal Health by 14.3% during the second quarter. JFS Wealth Advisors LLC now owns 1,949 shares of the company’s stock worth $152,000 after buying an additional 244 shares during the period. Dupont Capital Management Corp purchased a new position in Cardinal Health during the second quarter worth $164,000. Finally, First Personal Financial Services boosted its stake in Cardinal Health by 127.5% during the second quarter. First Personal Financial Services now owns 2,209 shares of the company’s stock worth $172,000 after buying an additional 1,238 shares during the period. 87.26% of the stock is owned by institutional investors.

About Cardinal Health

Cardinal Health, Inc is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also operates nuclear pharmacies and cyclotron facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, and provides services to healthcare companies.

Get a free copy of the Zacks research report on Cardinal Health (CAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cardinal Health (NYSE:CAH)

Receive News & Ratings for Cardinal Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.